VolitionRx is a publicly traded life sciences company focused on the development of blood-based diagnostics for different types of cancer. It believes that current diagnostic measures are too costly or inadequate, and to that end it is developing superior-grade, more cost-effective diagnosis tests. Currently, it is focused on detection of colon cancer, though it has expressed future plans to expand into detection measures for other cancer types.
When it comes to the biotechnology space, a company that seeks to break into a new threshold of medical innovation or bring-to-market a therapeutic concept that can aptly tackle one of today’s medical challenges strongly requires leadership that is both business- and science-savvy. VolitionRx has assembled an experienced team with a unique blend of scientific management and business expertise, so that its efforts to revolutionize cancer detection remain strengthened and focused.
Leading VolitionRx’s day-to-day operations is company President and Chief Executive Officer Cameron Reynolds, a savvy business professional with over 20 years of entrepreneurial executive experience in mining and biotechnology companies. He leverages heavy expertise in the management, structuring, and strategic planning of start-up companies in his current role.
In 1996, Mr. Reynolds planted his roots in the life science and biotechnology sectors when he began working for Integrated Coffee Technologies, a genetically modified coffee company. In a junior management position at this company, he was responsible for business plan development, office management, recruiting, and business development. Afterward, Mr. Reynolds went on to serve as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields, from 1998 to 2001. Notably, among Probio, Inc.’s many successful commercialization attempts was its marketization of transgenisis and cloning research from the University of Hawaii. In this capacity, Mr. Reynolds’ main responsibilities consisted of management of all legal and contract issues with the University of Hawaii; execution of patent strategy; management of all shareholder issues, including the company’s merger and its contractual and legal paperwork; head office management; budgetary control; and team development and recruitment.
In 2004, Reynolds started and served as Managing Director and Director of Mining House Limited, a mining company. In this role, he held several responsibilities, including identification of promising mining project prospects, coordination of the projects’ initial evaluations, and securing the projects’ financing, in efforts toward listing the companies on various stock exchanges, including the OTC. Since 2005 to the present, Mr. Reynolds has served as a board member for several companies, including: Atlantic Mining PLC; Carbon Mining PLC, Magellan Copper and Gold; KAL Energy Inc., Iofina Natural Gas PLC; Canyon Copper Corp.; and Hunter Bay Resources.
In total, VolitionRx’s management team has easily over 110 years of combined diverse, professional experience. The company’s other leaders leverage experience in finance and accounting, medicine with an emphasis on diagnostics, sales and marketing, statutory and regulatory requirements compliance, biotech research and development, scientific management, and many other areas.
For more information about VolitionRx, please visit: http://www.volitionrx.com
Let us hear your thoughts:
